Literature DB >> 8627755

Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells.

H Zhang1, G Dornadula, R J Pomerantz.   

Abstract

Endogenous reverse transcription (ERT) of retroviruses has long been considered a somewhat artificial process which only mimics reverse transcription occurring in target cells, as detergents or amphipathic peptides have classically been used to make the envelopes of retroviruses in these reaction systems permeable. Recently, several studies suggested that ERT of human immunodeficiency virus type 1 (HIV-1) might occur without detergent treatment. However, this phenomenon could be due to damage of the retroviral envelope during the process of virion purification or freezing and thawing. In this report, intravirion HIV-1 ERT, without detergent-induced permeabilization, is demonstrated to occur in the natural microenvironments of HIV-1 virions and is not caused by artificial processes. Therefore, this stage of the viral life cycle was termed natural ERT (NERT). The efficiency of NERT in HIV-1 virions was markedly augmented by several physiological substances in the extracellular milieu, such as polyamines and deoxyribonucleoside triphosphates. In addition, HIV-1 virions in seminal plasma samples harbored dramatically higher levels of full-length or nearly full-length reverse transcripts than virions isolated from peripheral blood plasma samples of HIV-1-seropositive men. When HIV-1 virions were incubated with seminal plasma samples, infectivity in initially nondividing cells was also significantly enhanced. Thus, we suggest that HIV-1 virions are actively altered by the extracellular microenvironment and that NERT may play an important role in viral infection of nondividing cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627755      PMCID: PMC190138     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers.

Authors:  P A Sherman; J A Fyfe
Journal:  Anal Biochem       Date:  1989-08-01       Impact factor: 3.365

2.  Recombinant HIV-1 nucleocapsid protein accelerates HIV-1 reverse transcriptase catalyzed DNA strand transfer reactions and modulates RNase H activity.

Authors:  J A Peliska; S Balasubramanian; D P Giedroc; S J Benkovic
Journal:  Biochemistry       Date:  1994-11-22       Impact factor: 3.162

3.  Integration of human immunodeficiency virus type 1 DNA in vitro.

Authors:  C M Farnet; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

4.  Functional domains of the capsid protein of human immunodeficiency virus type 1.

Authors:  T Dorfman; A Bukovsky; A Ohagen; S Höglund; H G Göttlinger
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

5.  Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro.

Authors:  C A Spina; J C Guatelli; D D Richman
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

6.  HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.

Authors:  J A Zack; S J Arrigo; S R Weitsman; A S Go; A Haislip; I S Chen
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

7.  Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication.

Authors:  F Lori; A Malykh; A Cara; D Sun; J N Weinstein; J Lisziewicz; R C Gallo
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

8.  Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression.

Authors:  S Y Kim; R Byrn; J Groopman; D Baltimore
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

9.  Nascent human immunodeficiency virus type 1 reverse transcription occurs within an enveloped particle.

Authors:  H Zhang; Y Zhang; T Spicer; D Henrard; B J Poiesz
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

10.  Infection of monocyte-derived macrophages with human immunodeficiency virus type 1 (HIV-1). Monocyte-tropic and lymphocyte-tropic strains of HIV-1 show distinctive patterns of replication in a panel of cell types.

Authors:  R Collman; N F Hassan; R Walker; B Godfrey; J Cutilli; J C Hastings; H Friedman; S D Douglas; N Nathanson
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

View more
  76 in total

Review 1.  Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1.

Authors:  A D Kashuba; J R Dyer; L M Kramer; R H Raasch; J J Eron; M S Cohen
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A.

Authors:  T Pushkarsky; G Zybarth; L Dubrovsky; V Yurchenko; H Tang; H Guo; B Toole; B Sherry; M Bukrinsky
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 3.  Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.

Authors:  A Bardsley-Elliot; C M Perry
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

4.  Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.

Authors:  Renato S Aguiar; Luciana J Costa; Helena S Pereira; Rodrigo M Brindeiro; Amilcar Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

5.  In vitro synthesis of long DNA products in reactions with HIV-RT and nucleocapsid protein.

Authors:  Reshma M Anthony; Jeffrey J Destefano
Journal:  J Mol Biol       Date:  2006-10-06       Impact factor: 5.469

6.  R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors.

Authors:  Françoise Gondois-Rey; Angelique Biancotto; Marcelo Antonio Fernandez; Lise Bettendroffer; Jana Blazkova; Katerina Trejbalova; Marjorie Pion; Ivan Hirsch
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

7.  Gag-Pol supplied in trans is efficiently packaged and supports viral function in human immunodeficiency virus type 1.

Authors:  M K Hill; C W Hooker; D Harrich; S M Crowe; J Mak
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

8.  Characterization of a late entry event in the replication cycle of human immunodeficiency virus type 2.

Authors:  D J Griffiths; M Dittmar; P Clapham; E Thomas
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

9.  Characterization of the behavior of functional viral genomes during the early steps of human immunodeficiency virus type 1 infection.

Authors:  Vanessa Arfi; Julia Lienard; Xuan-Nhi Nguyen; Gregory Berger; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

10.  Mutations in human immunodeficiency virus type 1 nucleocapsid protein zinc fingers cause premature reverse transcription.

Authors:  James A Thomas; William J Bosche; Teresa L Shatzer; Donald G Johnson; Robert J Gorelick
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.